POINT Biopharma Global Inc., (PNT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PNT Stock Price Chart Interactive Chart >
PNT Price/Volume Stats
|Current price||$7.38||52-week high||$10.98|
|Prev. close||$7.22||52-week low||$5.22|
|Day high||$7.52||Avg. volume||541,606|
|50-day MA||$6.90||Dividend yield||N/A|
|200-day MA||$7.80||Market Cap||767.70M|
POINT Biopharma Global Inc., (PNT) Company Bio
POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.
Most Popular Stories View All
PNT Latest News Stream
|Loading, please wait...|
PNT Latest Social Stream
View Full PNT Social Stream
Latest PNT News From Around the Web
Below are the latest news stories about POINT BIOPHARMA GLOBAL INC that investors may wish to consider to help them evaluate PNT as an investment opportunity.
Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidanceINDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the completion of enrollment for the randomization phase in the pivotal phase 3 SPLASH trial, on schedule and meeting previous guidance. SPLASH is a multi-
INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH). Under the terms of the agreements, POINT will receive the initial $260 million in upfront payments
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model 177Lu-PNT6555, the lead of the PNT2004 pan-cancer fibroblast activation protein-α (FAP-α) targeted program, is currently in a phase 1 trial INDIANAPOLIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development
In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on POINT Biopharma Global (PNT - Research Report), with a price target of $18.00. The company's shares closed yesterday at $5.72.According to TipRanks, Walsh is an analyst with an average return of -29.6% and a 21.88% success rate. Walsh covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Actinium Pharmaceuticals, and Plus Therapeutics.Currently, the analyst consensus on POINT Biopharma Global is a Strong Buy with an average price target of $19.57, implying a 242.13% upside from current levels.
Truist Financial analyst Nicole Germino maintained a Buy rating on POINT Biopharma Global (PNT - Research Report) today and set a price target of $14.00. The company's shares opened today at $5.96.Germino covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Assembly Biosciences, and Fusion Pharmaceuticals. According to TipRanks, Germino has an average return of -25.3% and a 20.00% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for POINT Biopharma Global with a $18.43 average price target, implying a 209.23% upside from current levels.
PNT Price Returns